• SENSEX
    NIFTY 50
Market

SPARC shares fall 10% on USFDA response letter for drug Taclantis

Updated : February 12, 2020 09:55 AM IST

The company is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised.
The drug is used for chemotherapy and is expected to compete with market leader Abraxane.
SPARC shares fall 10% on USFDA response letter for drug Taclantis

You May Also Like

Live TV
Advertisement